Lisa Egbuonu-Davis Sells 2,546 Shares of Phreesia, Inc.

Lisa Egbuonu-Davis sold 2,546 shares of Phreesia, Inc. (NYSE:PHR) on June 25, 2026. This transaction, valued at $24,263.38, was part of a planned sale. Shares were sold at an average price of $9.53 each.

Insider Buying and Selling at Phreesia, Inc.

On June 25, 2026, Lisa Egbuonu-Davis sold 2,546 shares at an average price of $9.53 as part of a planned transaction. The day before, on June 24, 2026, several insiders, including Lainie Goldstein, Mark Douglas Smith, Ramin Sayar, Lisa Egbuonu-Davis, and Gillian Munson, each bought 19,290 shares at an average price of $9.59.

Other Institutional Activity in Phreesia, Inc.

Several institutional investors have been active in Phreesia, Inc. Pale Fire Capital SE opened a new position with 8,649,329 shares worth about $72.5 million. BlackRock, Inc. increased its stake by 284,445 shares, now holding 5,920,469 shares valued at approximately $49.6 million. Vanguard Portfolio Management LLC also opened a new position, acquiring 3,335,121 shares worth about $27.9 million. Vanguard Capital Management LLC followed suit with a new stake of 2,479,247 shares, valued at roughly $20.8 million. AQR Capital Management LLC significantly increased its position by 1,415,465 shares, reaching a total of 1,852,559 shares worth about $15.5 million.

Phreesia, Inc. Stock Down 17.1%

Shares of Phreesia, Inc. (NYSE:PHR) traded near $9.13 on Saturday. The company has a market cap of $622.4 million, a P/E ratio of 62.9, and a forward P/E of 6.3. With a beta of 0.884, the stock has a 52-week low of $7.77 and a high of $32.76. Its moving averages are $9.38 over 50 days and $15.21 over 200 days. Phreesia maintains a current ratio of 1.757 and a quick ratio of 1.433, alongside a debt-to-equity ratio of 25.775.

Recent Earnings

Phreesia, Inc. reported revenue of $495.6 million with a growth rate of 12.9%. The company's earnings per share (EPS) stood at $0.16. It achieved a net margin of 1.85% and a return on equity (ROE) of 2.86%. The next earnings release is expected on September 3, 2026.

Analysts Set New Price Targets

On May 29, 2026, Truist Securities maintained a hold rating with a $12.00 price target. Citigroup also maintained its hold rating with a $12.00 target on May 28, 2026. Canaccord Genuity and DA Davidson both maintained buy ratings with price targets of $16.00 and $14.00, respectively. The consensus recommendation is a 'buy' with an average price target of $13.94 based on 17 analyst opinions.

About Phreesia, Inc.

Phreesia, Inc. provides a software and payment platform for the healthcare industry in the United States and Canada. Its solutions include appointment optimization, referral management, and AI-based patient communications. The company offers integrated payment and financing solutions to healthcare organizations, aiming to improve cash collections and offer flexible payment options. Headquartered in Wilmington, Delaware, Phreesia serves a variety of healthcare entities and was founded in 2005.

Bottom Line

Lisa Egbuonu-Davis's sale of Phreesia shares is part of planned insider activity. Phreesia, Inc. is actively followed by institutional investors like Vanguard and BlackRock, indicating interest in the company's growth. Investors should note that insider transactions and 13F filings are backward-looking and may not reflect current positions.